Fair Value Measurements - Additional Information (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($)	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($)	Sep. 30, 2011 shares	Jan. 31, 2013 shares	Dec. 31, 2012 shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	527,181		527,181
Fair value | $	$ 24,780,173		$ 24,780,173
Level 1 | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value | $	$ 24,780,173		$ 24,780,173
Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	500,000		500,000
Duration of exchange rights			7 years
Exchange right convertible conversion ratio			0.01
Number of exchange right sold					675,000
Exchange rights
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $			$ 27,500
Exchange rights | Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ (1,500)	$ 6,650	$ 27,500	$ 4,700
2012 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock							912,543
Warrants outstanding	265,161		265,161
2013 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock						833,530
Warrants outstanding	12,123		12,123
Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ (25,883)	$ 363,285	$ 1,428,948	$ 341,711